Search research articles
Contact Us
Filters
Showing results (21-30 of 82) with videos related to
Page
of 9
Sort By:
The New England Journal of Medicine
|
April 12, 2018
The FDA Breakthrough-Drug Designation - Four Years of Experience
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine
|
March 28, 2014
New FDA breakthrough-drug category--implications for patients
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|
October 4, 2013
Institutional corruption of pharmaceuticals and the myth of safe and effective drugs
Donald W Light, Joel Lexchin, Jonathan J Darrow
The New England Journal of Medicine
|
July 3, 2014
New FDA breakthrough-drug category--implications for patients
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
JAMA
|
August 3, 2021
FDA Regulation and Approval of Medical Devices: 1976-2020
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine
|
April 9, 2015
Expanded access to investigational drugs
Ameet Sarpatwari, Jonathan J Darrow, Aaron S Kesselheim
Nature Biotechnology
|
January 4, 2019
An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?
Timo Minssen, Aaron S Kesselheim, Jonathan J Darrow
The New England Journal of Medicine
|
December 7, 2017
Speed, Safety, and Industry Funding - From PDUFA I to PDUFA VI
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
The American Surgeon
|
December 21, 2020
Evidence Supporting the Value of Surgical Procedures: Can We Do Better?
Jonathan J Darrow, Christopher T Robertson, Willard S Kasoff
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 4, 2018
A Method for Approximating Future Entry of Generic Drugs
Reed F Beall, Jonathan J Darrow, Aaron S Kesselheim
Page
of 9
Search research articles
Search
Showing results (21-30 of 82) with videos related to
Sort By:
Page
of 9
The New England Journal of Medicine
|
April 12, 2018
The FDA Breakthrough-Drug Designation - Four Years of Experience
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine
|
March 28, 2014
New FDA breakthrough-drug category--implications for patients
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
|
October 4, 2013
Institutional corruption of pharmaceuticals and the myth of safe and effective drugs
Donald W Light, Joel Lexchin, Jonathan J Darrow
The New England Journal of Medicine
|
July 3, 2014
New FDA breakthrough-drug category--implications for patients
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
JAMA
|
August 3, 2021
FDA Regulation and Approval of Medical Devices: 1976-2020
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine
|
April 9, 2015
Expanded access to investigational drugs
Ameet Sarpatwari, Jonathan J Darrow, Aaron S Kesselheim
Nature Biotechnology
|
January 4, 2019
An export-only exception to pharmaceutical patents in Europe: should the United States follow suit?
Timo Minssen, Aaron S Kesselheim, Jonathan J Darrow
The New England Journal of Medicine
|
December 7, 2017
Speed, Safety, and Industry Funding - From PDUFA I to PDUFA VI
Jonathan J Darrow, Jerry Avorn, Aaron S Kesselheim
The American Surgeon
|
December 21, 2020
Evidence Supporting the Value of Surgical Procedures: Can We Do Better?
Jonathan J Darrow, Christopher T Robertson, Willard S Kasoff
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 4, 2018
A Method for Approximating Future Entry of Generic Drugs
Reed F Beall, Jonathan J Darrow, Aaron S Kesselheim
Page
of 9